Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Yamazaki

Showing results (211-220 of 252) with videos related to

Pageof 26
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2024
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal CancerNaoko Iida, Mitsuho Imai, Wataru Okamoto, et al.
International Journal of Clinical Oncology|December 16, 2019
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS studyToshikazu Moriwaki, Shota Fukuoka, Toshiki Masuishi, et al.
British Journal of Cancer|October 4, 2017
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) studyEiji Shinozaki, Takayuki Yoshino, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|March 1, 2023
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutantChikako Nakai, Sachiyo Mimaki, Koutatsu Matsushima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal CancerTimothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, et al.
The Oncologist|July 16, 2020
Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)Hironaga Satake, Takeshi Kato, Koji Oba, et al.
The Oncologist|September 13, 2017
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational StudyToshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, et al.
Cancer Science|October 19, 2020
FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancerHiroko Hasegawa, Hiroya Taniguchi, Yoshiaki Nakamura, et al.
International Journal of Clinical Oncology|July 21, 2022
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and RectumTakahiko Ito, Atsuo Takashima, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|March 4, 2026
Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and RectumRyosuke Kawagoe, Toshikazu Moriwaki, Kentaro Yamazaki, et al.
Pageof 26

Showing results (211-220 of 252) with videos related to

Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2024
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal CancerNaoko Iida, Mitsuho Imai, Wataru Okamoto, et al.
International Journal of Clinical Oncology|December 16, 2019
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS studyToshikazu Moriwaki, Shota Fukuoka, Toshiki Masuishi, et al.
British Journal of Cancer|October 4, 2017
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) studyEiji Shinozaki, Takayuki Yoshino, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|March 1, 2023
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutantChikako Nakai, Sachiyo Mimaki, Koutatsu Matsushima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal CancerTimothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, et al.
The Oncologist|July 16, 2020
Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)Hironaga Satake, Takeshi Kato, Koji Oba, et al.
The Oncologist|September 13, 2017
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational StudyToshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, et al.
Cancer Science|October 19, 2020
FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancerHiroko Hasegawa, Hiroya Taniguchi, Yoshiaki Nakamura, et al.
International Journal of Clinical Oncology|July 21, 2022
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and RectumTakahiko Ito, Atsuo Takashima, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|March 4, 2026
Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and RectumRyosuke Kawagoe, Toshikazu Moriwaki, Kentaro Yamazaki, et al.
Pageof 26